Phase 3 studies of pembrolizumab fail to meet key survival endpoints
Phase 3 studies of pembrolizumab — with chemotherapy for metastatic castration-resistant prostate cancer and with lenvatinib for unresectable liver cancer — did not meet primary endpoints of survival, according to the agent’s manufacturer.Pembrolizumab, (Keytruda, Merck), an anti-PD-1 antibody, has been approved as monotherapy and in combination with other therapies for patients with a variety of cancers.The double-blind, randomized phase 3 KEYNOTE-921 trial assessed pembrolizumab among men with chemotherapy-naive metastatic castration-resistant prostate cancer whose diseaseRead More
